Celularity Inc.
NASDAQ:CELUBiotechnology
+$1.22 today
- Market cap
- $52.97M
- Beta
- 0.54
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$3.58
Volume 0.00M
Average 0.13M
CELU Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Celularity Inc.NASDAQ: CELU
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development declines year over year
Q4 FY2025 research & development of $3.35M fell 12.6% year over year, ahead of the -13.6% change in trailing-twelve-month research & development. Sequentially, it fell 27.2% from the prior quarter. Over 3 fiscal years it compounded at -42.3% a year.
Context
- Research & development amounted to 56.6% of revenue in FY2025, up 24.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -12.6% holds above the trailing-twelve-month pace of -13.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 15.03M USD
- Year-over-year change
- -13.6%
- 4-year CAGR
- -35.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.03M | -13.6% |
| FY2024 | 2024-12-31 | 17.39M | -42.9% |
| FY2023 | 2023-12-31 | 30.47M | -61.1% |
| FY2022 | 2022-12-31 | 78.36M | -11.3% |
| FY2021 | 2021-12-31 | 88.35M | — |
Research & Development vs competitors
How CELU compares with its peers on the latest reported figures
- CELU's LTM Dec 2025 research & development of $15.03M is the lowest of the 4 companies compared; the peer median is $23.45M.
- Its year-over-year change of -13.6% is the 3rd highest of 4, against a peer median of -1.8%.
- Research & development amounts to 56.6% of revenue for CELU, versus a peer median of 53.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B | +90463.6% | +15.1% | — | |
| LTM Mar 2026 | $23.45M | -1.8% | -5.3% | — | |
| LTM Jun 2026 | $18.74M | -30.0% | -3.0% | 53.4% | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| Peer median (excluding CELU) | $23.45M | -1.8% | -3.0% | 53.4% | |
Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.34M | 17.98M | 22.77M | 54.22M | 26.55M |
| Cost of Revenue | 9.65M | 19.67M | 16.02M | 14.99M | 6.36M |
| Gross Profit | 11.68M | (1.69M) | 6.76M | 39.23M | 20.19M |
| Gross Margin | 54.8% | -9.4% | 29.7% | 72.4% | 76.0% |
| Research & Development | 88.35M | 78.36M | 30.47M | 17.39M | 15.03M |
| Selling, General & Admin | 71.34M | 66.02M | 50.58M | 58.64M | 51.27M |
| Operating Expenses | 120.74M | 23.91M | 199.04M | 77.59M | 81.5M |
| Depreciation & Amortization | 8.82M | 9.44M | 9.32M | 7.92M | 7.3M |
| EBITDA | (88.11M) | (138.83M) | (183.95M) | (43.71M) | (77.66M) |
| EBITDA Margin | -413.0% | -772.4% | -807.8% | -80.6% | -292.5% |
| Operating Income | (109.06M) | (25.6M) | (192.29M) | (38.36M) | (61.31M) |
| Operating Margin | -511.2% | -142.4% | -844.4% | -70.7% | -230.9% |
| Interest Income | 332K | 365K | 320K | 331K | 262K |
| Interest Expense | 3.17M | 0 | 3.02M | 6.26M | 6.75M |
| Other Income / Expenses | 8.96M | 39.81M | (4M) | (19.53M) | (30.41M) |
| Income Before Tax | (100.1M) | 14.21M | (196.29M) | (57.89M) | (91.71M) |
| Pre-Tax Margin | -469.2% | 79.0% | -862.0% | -106.8% | -345.4% |
| Income Tax Expense | 20K | 13K | 10K | 0 | 3K |
| Net Income | (100.12M) | 14.19M | (196.3M) | (57.89M) | (91.8M) |
| Net Margin | -469.3% | 79.0% | -862.0% | -106.8% | -345.8% |
| EPS (Basic) | (7.87) | 1.01 | (11.02) | (2.64) | (3.59) |
| EPS (Diluted) | (7.87) | 0.95 | (11.02) | (2.64) | (3.59) |
| Weighted Avg Shares | 12.73M | 13.99M | 17.81M | 21.89M | 25.6M |
| Weighted Avg Shares (Diluted) | 12.73M | 14.98M | 17.81M | 21.89M | 25.6M |
Celularity Inc.
NASDAQ:CELU
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.